- Home
- AGIO vs SDHC Comparison
AGIO vs SDHC Comparison
Compare AGIO & SDHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AGIO | SDHC |
|---|---|---|
| Founded | 2007 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 176.7M |
| IPO Year | 2013 | 2024 |
Fundamental Metrics
Financial Performance| Metric | AGIO | SDHC |
|---|---|---|
| Price | $27.39 | $21.89 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 5 |
| Target Price | ★ $32.13 | $16.70 |
| AVG Volume (30 Days) | ★ 2.6M | 81.8K |
| Earning Date | 10-30-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $44,791,000.00 | ★ $998,173,000.00 |
| Revenue This Year | $28.75 | $0.47 |
| Revenue Next Year | $139.45 | $7.65 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 36.26 | 10.26 |
| 52 Week Low | $22.24 | $15.00 |
| 52 Week High | $46.00 | $33.18 |
Technical Indicators
Market Signals| Indicator | AGIO | SDHC |
|---|---|---|
| Relative Strength Index (RSI) | 37.05 | 69.31 |
| Support Level | $26.80 | $19.72 |
| Resistance Level | $28.61 | $22.41 |
| Average True Range (ATR) | 1.19 | 1.12 |
| MACD | 0.25 | 0.24 |
| Stochastic Oscillator | 56.00 | 92.82 |
Price Performance
Historical ComparisonAbout AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About SDHC Smith Douglas Homes Corp.
Smith Douglas Homes Corp is a company engaged in the design, construction, and sale of single-family homes in some of the highest growth and desirable markets in the Southeastern United States. It is organized into eight geographical divisions which comprise two reportable segments. Its Southeast segment consists of Atlanta, Central Georgia, Charlotte, Greenville, and Raleigh divisions. Its Central segment consists of Alabama, Houston, and Nashville divisions.